Core Viewpoint - Spring Medical (688236) has shown significant growth in revenue and net profit for the first three quarters of 2025, indicating strong operational performance and potential investment opportunities. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 756 million yuan, a year-on-year increase of 48.75% [2] - The net profit attributable to shareholders reached 192 million yuan, reflecting a substantial year-on-year growth of 213.21% [2] - The net profit for the third quarter alone was 77.06 million yuan, marking a remarkable increase of 531.12% compared to the same period last year [5] Shareholder and Stock Information - As of September 30, 2025, the number of shareholders increased to 6,149, up by 4.11% from June 30, 2025 [3] - The average number of shares held per shareholder decreased from 48,800 to 46,900, with an average holding value of 1.1684 million yuan [3] Dividend and Corporate Governance - The company plans to distribute a cash dividend of 2.10 yuan per 10 shares (including tax), totaling approximately 80.26 million yuan, which represents 41.90% of the net profit [3][5] - The board has approved a proposal to abolish the supervisory board, transferring its functions to the audit committee of the board, pending shareholder approval [3][5] Asset Impairment - For the first three quarters of 2025, the company recognized an asset impairment provision totaling 45.71 million yuan, primarily due to bad debt losses and inventory write-downs [3]

Core Viewpoint - Spring Medical is a leading company in the domestic orthopedic implant medical device sector, focusing on joint prosthetics and spinal implants, with a strong technical and full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Spring Medical achieved a revenue of 756 million yuan, ranking 25th among 50 companies in the industry, with the industry leader, Yingke Medical, generating 7.425 billion yuan [2] - The net profit for the same period was 192 million yuan, placing the company 20th in the industry, while the top performer, Lepu Medical, reported a net profit of 996 million yuan [2] - The company reported a year-on-year revenue growth of 48.8% and a net profit growth of 213.2% for the first nine months of 2025, driven by international market expansion and increased export revenue [6] Group 2: Financial Ratios - As of Q3 2025, Spring Medical's debt-to-asset ratio was 15.65%, lower than the previous year's 19.98% and below the industry average of 23.66%, indicating strong solvency [3] - The gross profit margin for the same period was 67.27%, slightly down from 69.30% year-on-year but significantly higher than the industry average of 48.78%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 4.11% to 6,149, while the average number of circulating A-shares held per household decreased by 3.95% to 46,900 shares [5] Group 4: Management Compensation - The chairman, Shi Wenling, received a salary of 341,100 yuan in 2024, a decrease of 58,100 yuan from 2023, while the general manager, Shi Chunsheng, saw an increase in salary to 525,700 yuan [4] Group 5: Future Outlook - The company plans to distribute a cash dividend of 2.10 yuan per 10 shares, totaling 80.26 million yuan, and forecasts net profits of 280 million yuan, 360 million yuan, and 440 million yuan for 2025 to 2027 [6] - New product approvals in sports medicine, robotics, and dentistry are expected to contribute to future revenue growth [7]

Group 1 - Spring Medical (01858.HK) has seen a significant increase in its stock price, rising over 10% [1] - As of the latest update, the stock is up 10.66%, trading at 18.37 HKD [1] - The trading volume reached 45.461 million HKD [1]

Market Overview - The Hang Seng Index fell by 0.89%, down 232 points, closing at 26,050 points, while the Hang Seng Tech Index dropped by 1.91% [1] - The early trading volume in the Hong Kong stock market reached HKD 142.3 billion [1] Biotechnology Sector - The Hang Seng Biotechnology Index rebounded by 2.16%, with notable gains in several stocks: - InnoCare Pharma (09606) surged by 10.88% - 3SBio (01530) increased by over 10% - Innovent Biologics rose by 6.82% - Kelun-Biotech (06990) gained 5.69% [1] - Fosen Pharmaceuticals (01652) saw a significant increase, with a peak rise of nearly 74% and an early gain of 59.42% following the approval of Enzalutamide soft capsules and the potential selection of Metformin and Empagliflozin for national procurement [1] - Rongchang Biopharma (09995) rose by 6.75%, reporting a 40% year-on-year revenue growth and a significant reduction in losses for the first three quarters [1] Medical Sector - Spring Medical (01858) increased by over 21%, turning a profit of HKD 77.06 million in the third quarter as the company actively expands its international market [2] New Stocks Performance - Newly listed Dipo Technology (01384) continued to rise, gaining 18.97% and doubling its stock price within three days of listing [3] Financial Sector - China Everbright Bank (06818) fell by 5% post-earnings, with both revenue and profit declining in the third quarter, facing pressure from fair value changes [4] Other Notable Stocks - Huahao Zhongtian Pharmaceutical-B (02563) experienced a significant drop of over 37% due to a large unlock of shares after one year of listing [5] - Lion Holdings (02562) plummeted over 24% to a new low, planning to issue convertible bonds to raise approximately HKD 260 million for investments in gold and related products [6] - Air China (00753) dropped over 8%, with a more than 11% decline in net profit for the third quarter, and plans to raise up to HKD 20 billion through A-share placement [7]

Group 1: Hong Kong Stock Market Updates - China Metallurgical Group (01618) saw a decline of over 5%, reporting a revenue of 335.09 billion yuan for the first three quarters, a year-on-year decrease of 18.79%, and a net profit of 3.97 billion yuan, down 41.88% [1] - Fosen Pharmaceutical (01652) surged nearly 74% after announcing that its subsidiary received approval for the "Enzalutamide Soft Capsule" from the National Medical Products Administration of China [1] - Sanhua Intelligent Control (02050) increased over 3%, with a revenue of 24.03 billion yuan for the first three quarters, a year-on-year growth of 16.86%, and a net profit of 3.24 billion yuan, up 40.85% [1] - Rongchang Biopharmaceutical (09995) rose over 5%, reporting a revenue of approximately 1.72 billion yuan, a year-on-year increase of 42.27%, and a net loss of about 551 million yuan, narrowing by 48.6% [1] - New Special Energy (01799) fell nearly 8%, with a revenue of 11.66 billion yuan and a net loss of 526 million yuan for the first three quarters [1] Group 2: Additional Hong Kong Stock Market Updates - Chuny Medical (01858) increased over 10%, reporting a revenue of 756 million yuan, a year-on-year growth of 48.75%, and a net profit of 192 million yuan, up 213.21% [2] - Innovent Biologics (01801) rose over 4%, achieving total product revenue exceeding 3.3 billion yuan in Q3, maintaining a strong year-on-year growth of about 40% [2] - Longpan Technology (02465) increased over 6%, with a revenue of approximately 5.83 billion yuan, a year-on-year growth of 2.91%, and a net loss of about 110 million yuan, narrowing by 63.53% [2] - 3SBio (01530) saw an early morning increase of nearly 7%, following a significant deal with Pfizer worth up to $12.5 billion [2] - China CNR Corporation (01766) fell over 8%, reporting a revenue of approximately 183.87 billion yuan, a year-on-year increase of 20.49%, and a net profit of about 9.96 billion yuan, up 37.53% [2] Group 3: US Stock Market Updates - Carvana (CVNA.US) dropped over 13%, reporting a Q3 revenue growth of 54.5% to $5.65 billion, exceeding analyst expectations [3] - Alphabet (GOOGL.US) rose nearly 2%, with Q3 revenue surpassing $100 billion, driven by strong AI demand boosting cloud business [3] - Meta Platforms (META.US) fell over 11%, reporting Q3 revenue of $51.2 billion, a 26% year-on-year increase, but net profit significantly below expectations due to a one-time tax expense [4] - Bitcoin-related stocks experienced declines, with Strategy (MSTR.US) down nearly 7% and Coinbase (COIN.US) down over 5% [4] - eBay (EBAY.US) plummeted 15%, marking its largest drop in over 20 years despite exceeding sales expectations [4] Group 4: Additional US Stock Market Updates - Comcast (CMCSA.US) fell 4%, losing 104,000 broadband users in Q3, marking the tenth consecutive quarter of user decline [5] - CoreWeave (CRWV.US) dropped over 6% after shareholders rejected a proposed acquisition [5] - Roblox (RBLX.US) fell over 15%, reporting Q3 revenue of $1.4 billion, a 48% year-on-year increase, but widening net losses [5] - Moderna (MRNA.US) rose over 13%, reportedly in talks for a large-scale acquisition with a major pharmaceutical company [6] - Altria (MO.US) fell over 7%, reporting adjusted EPS of $1.45, in line with market consensus, but net revenue declined by 1.7% [6]

Core Viewpoint - Spring Medical (01858) experienced a significant stock increase of over 10%, attributed to strong financial performance in the first three quarters of 2025, with notable growth in revenue and net profit [1] Financial Performance - The company reported a revenue of 756 million yuan, representing a year-on-year increase of 48.75% [1] - Net profit attributable to shareholders reached 192 million yuan, showing a substantial year-on-year growth of 213.21% [1] - In the third quarter alone, revenue was 268 million yuan, reflecting a remarkable year-on-year growth of 109.51% [1] - The net profit for the third quarter was 77.06 million yuan, marking a turnaround from losses to profitability [1] Market Expansion and Competitive Advantage - Huatai Securities noted that the company's rapid growth in the third quarter is primarily due to its steady progress in international market expansion and increasing export revenue [1] - The company has successfully passed CE annual system audits and supervision audits for its hip, knee, and spine product lines, indicating strong international market competitiveness [1] - The knee prosthesis system received FDA 510(K) approval, showcasing the company's technological advantages and establishing a foundation for sustained international sales growth [1]

Core Viewpoint - Spring Medical (01858) has experienced a significant stock price increase of over 10%, attributed to strong financial performance in Q3 2025, with notable revenue and profit growth [1] Financial Performance - The company reported a revenue of 756 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.75% [1] - Net profit attributable to shareholders reached 192 million yuan, showing a substantial year-on-year growth of 213.21% [1] - In Q3 alone, the company achieved a revenue of 268 million yuan, marking a remarkable year-on-year increase of 109.51% [1] - The net profit for Q3 was 77.06 million yuan, indicating a turnaround from loss to profit [1] Market Expansion and Product Development - Huatai Securities attributes the rapid growth in Q3 to the company's steady progress in international market expansion and increasing export revenue [1] - The company has successfully passed CE annual system audits and supervision audits for its hip, knee, and spine product lines, indicating strong international competitiveness [1] - The knee prosthesis system has received FDA 510(k) approval, showcasing the company's technological advantages and establishing a foundation for continued growth in international sales [1]

Company Overview - Spring Medical is a Chinese company primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with a focus on joint prosthetics and spinal implants [1] - The company was established on February 12, 1998, and went public on December 30, 2021 [1] - Its main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1] - The company's revenue composition is predominantly from medical device products at 99.89%, with a minor contribution of 0.11% from other sources [1] Market Performance - As of October 31, Spring Medical's stock price increased by 5.03%, reaching 26.50 CNY per share, with a trading volume of 26.14 million CNY and a turnover rate of 0.35% [1] - The total market capitalization of Spring Medical is 10.165 billion CNY [1] Shareholder Information - Among the top circulating shareholders, one fund from China Europe Fund, the China Europe Prosperity Selected Mixed A (020876), entered the top ten in the third quarter, holding 2.8326 million shares, which is 0.74% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 3.5974 million CNY [2] Fund Performance - The China Europe Prosperity Selected Mixed A fund, managed by Zhang Xueming, has a total asset size of 6.741 billion CNY [3] - Since its inception, the fund has achieved a return of 70.66%, with a year-to-date return of 52.9% and a one-year return of 58.85% [2][3]

Core Insights - Spring Medical (688236.SH) reported a total revenue of 756 million yuan for Q3 2025, with a net profit attributable to shareholders of 192 million yuan and a net cash inflow from operating activities of 175 million yuan [1]. Financial Performance - The company's latest debt-to-asset ratio stands at 15.65% [3]. - The gross profit margin is 67.27%, which is a decrease of 2.03 percentage points compared to the same period last year [3]. - The return on equity (ROE) is reported at 6.42% [3]. - The diluted earnings per share (EPS) is 0.50 yuan [3]. - The total asset turnover ratio is 0.22 times, ranking 79th among disclosed peers [3]. - The inventory turnover ratio is 0.44 times, ranking 127th among disclosed peers [3]. Shareholder Structure - The number of shareholders is 6,164, with the top ten shareholders holding a total of 249 million shares, accounting for 64.88% of the total share capital [3]. - The top ten shareholders and their respective holdings are as follows: - Shi Chunbao: 31.3 million shares - Yue Mujun: 24.8 million shares - Beijing Panmao Investment Management Co., Ltd.: 4.50 million shares - Hong Kong Central Clearing Limited: 0.77 million shares - Huaxia Bank Co., Ltd.: 0.74 million shares - Huang Dong: 0.66 million shares - Beijing Panmao Investment Management Co., Ltd.: 0.65 million shares - Agricultural Bank of China: 0.55 million shares - Huatai Securities Asset Management: 0.43 million shares - Beijing Chunli Zhengda Medical Device Co., Ltd.: 0.36 million shares [3].

（股 份 代 號：1858） 將於2025年11月19日舉行之H股類別股東大會之代表委任表格 本人╱吾等 （附註1） ， 地址為 ， 為北京市春立正達醫療器械股份有限公司（「本公司」）股本中每股面值人民幣1.00元之 股 H股 （附註2） 之登記持有人，茲委任H股類別股東大會主席或 （附註3） ， 為本人╱吾等之受委任代表，代表本人╱吾等出席將於2025年11月19日（星期三）下午二時正（或緊隨於同日舉行的本公司A股類 別股東大會結束後）在中國北京市通州區通州經濟開發區南區鑫覓西二路10號舉行的H股類別股東大會及其任何續會，以考慮 並酌情通過召開H股類別股東大會通知所載之決議案，並於H股類別股東大會及其任何續會上代表本人╱吾等以本人╱吾等之 名義依照以下指示 （附註4） 就該決議案投票。 有關決議案的進一步詳情載於本公司日期為2025年10月30日的通函內。 | | 特別決議案 | 贊成 | （附註4） | 反對 | （附註4） | 棄權 | （附註4） | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. | 審議及批准取消監事會及建議修訂章程細則 ...